Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders

Journal of Alzheimer's Disease

Volumn 9, Issue 3, 2006, Pages 293-348

  Abdi, Fadi ^a   Quinn, Joseph F ^b   Jankovic, Joseph ^c   McIntosh, Martin ^d   Leverenz, James B ^e   Peskind, Elaine ^e   Nixon, Randy ^b   Nutt, John ^b   Chung, Katherine ^b   Zabetian, Cyrus ^e   Samii, Ali ^e   Lin, Melanie ^a   Hattan, Stephen ^a   Pan, Catherine ^e   Wang, Yan ^e   Jin, Jinghua ^e   Zhu, David ^e   Li, G Jane ^e   Liu, Yan ^d   Waichunas, Dana ^b   Montine, Thomas J ^e   Zhang, Jing ^e   more..

^a Applied Biosystems Framingham   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer disease; Biomarkers; Parkinson disease; Proteomics

Indexed keywords

BIOLOGICAL MARKER;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; AUTOPSY; CEREBROSPINAL FLUID ANALYSIS; CHROMATOGRAPHY; CONTROLLED STUDY; DEGENERATIVE DISEASE; DEMENTIA WITH LEWY BODY; DISEASE COURSE; FEMALE; HUMAN; ISOBARIC TAGGING FOR RELATIVE AND ABSOLUTE PROTEIN QUANTIFICATION; LEWY BODY; MALE; PARKINSON DISEASE; PATIENT MONITORING; PRIORITY JOURNAL; PROTEOMICS; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; WESTERN BLOTTING;

EID: 33747409456     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2006-9309     Document Type: Article

References (57)

1. I. Alafuzoff, R. Adolfsson, I. Grundke-Iqbal and B. Winblad, Blood-brain barrier in Alzheimer dementia and in non-demented elderly. An immunocytochemical study, Acta Neuropathol (Berl) 73 (1987), 160-166.
2. N. Andreasen and K. Blennow, CSF biomarkers for mild cognitive impairment and early Alzheimer's disease, Clin Neurol Neurosurg 107 (2005), 165-173.
3. B.J. Bacskai, W.E. Klunk, C.A. Mathis and B.T. Hyman, Imaging amyloid-beta deposits in vivo, J Cereb Blood Flow Metab 22 (2002), 1035-1041.
4. K. Blennow, CSF biomarkers for Alzheimer's disease: use in early diagnosis and evaluation of drug treatment, Expert Rev Mol Diagn 5 (2005), 661-672.
5. K. Blennow, P. Fredman, A. Wallin, C.G. Gottfries, I. Karlsson, G. Langstrom, I. Skoog, L. Svennerholm and C. Wikkelso, Protein analysis in cerebrospinal fluid. II. Reference values derived from healthy individuals 18-88 years of age, Eur Neurol 33 (1993), 129-133.
6. O. Carrette, I. Demalte, A. Scherl, O. Yalkinoglu, G. Corthals, P. Burkhard, D.F. Hochstrasser and J.C. Sanchez, A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease, Proteomics 3 (2003), 1486-1494.
7. L.H. Choe, M.J. Dutt, N. Relkin and K.H. Lee, Studies of potential cerebrospinal fluid molecular markers for Alzheimer's disease, Electrophoresis 23 (2002), 2247-2251.
8. G.L. Corthals, V.C. Wasinger, D.F. Hochstrasser and J.C. Sanchez, The dynamic range of protein expression: a challenge for proteomic research, Electrophoresis 21 (2000), 1104-1115.
9. P. Davidsson and M. Sjogren, The use of proteomics in biomarker discovery in neurodegenerative diseases, Dis Markers 21 (2005), 81-92.
10. P. Davidsson, A. Westman-Brinkmalm, C.L. Nilsson, M. Lindbjer, L. Paulson, N. Andreasen, M. Sjogren and K. Blennow, Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients, Neuroreport 13 (2002), 611-615.
11. U. Eder, B. Leitner, R. Kirchmair, P. Pohl, K.A. Jobst, A.D. Smith, J. Mally, A. Benzer, P. Riederer, H. Reichmann, A. Saria and H. Winkler, Levels and proteolytic processing of chromogranin A and B and secretogranin II in cerebrospinal fluid in neurological diseases, J Neural Transm 105 (1998), 39-51.
12. C. Flicker, S.H. Ferris and B. Reisberg, Mild cognitive impairment in the elderly: predictors of dementia, Neurology 41 (1991), 1006-1009.
13. M.F. Folstein, S.E. Folstein and P.R. McHugh, "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician, J Psychiatr Res 12 (1975), 189-198.
14. D. Galasko, R. Katzman, D.P. Salmon and L. Hansen, Clinical and neuropathological findings in Lewy body dementias, Brain Cogn 31 (1996), 166-175.
15. D.J. Gelb, E. Oliver and S. Gilman, Diagnostic criteria for Parkinson disease, Arch Neurol 56 (1999), 33-39.
16. A. Gupta, A. Watkins, P. Thomas, R. Majer, N. Habubi, G. Morris and K. Pansari, Coagulation and inflammatory markers in Alzheimer's and vascular dementia, Int J Clin Pract 59 (2005), 52-57.
17. B.N. Hammack, K.Y. Fung, S.W. Hunsucker, M.W. Duncan, M.P. Burgoon, G.P. Owens and D.H. Gilden, Proteomic analysis of multiple sclerosis cerebrospinal fluid, Mult Scler 10 (2004), 245-260.
18. H. Hochstrasser, P. Bauer, U. Walter, S. Behnke, J. Spiegel, I. Csoti, B. Zeiler, A. Bornemann, J. Pahnke, G. Becker, O. Riess and D. Berg, Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease, Neurology 63 (2004), 1912-1917.
19. Y. Hu, J.P. Malone, A.M. Fagan, R.R. Townsend and D.M. Holtzman, Comparative proteomics analysis of intra- and inter-individual variation in human cerebrospinal fluid, Mol Cell Proteomics 4 (2005), 2000-2009.
20. A.J. Hughes, S.E. Daniel, L. Kilford and A.J. Lees, Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases, J Neurol Neurosurg Psychiatry 55 (1992), 181-184.
21. A.J. Hughes, S.E. Daniel, Y. Ben-Shlomo and A.J. Lees, The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service, Brain 125 (2002), 861-870.
22. J. Jankovic, A.H. Rajput, M.P. McDermott and D.P. Perl, The evolution of diagnosis in early Parkinson disease. Parkinson Study Group, Arch Neurol 57 (2000), 369-372.
23. G. Johnson, D. Brane, W. Block, D.P. van Kammen, J. Gurklis, J.L. Peters, R.J. Wyatt, D.G. Kirch, H.A. Ghanbari and C.R. Merril, Cerebrospinal fluid protein variations in common to Alzheimer's disease and schizophrenia, Appl Theor Electrophor 3 (1992), 47-53.
24. E.A. Kapp, F. Schutz, L.M. Connolly, J.A. Chakel, J.E. Meza, C.A. Miller, D. Fenyo, J.K. Eng, J.N. Adkins, G.S. Omenn and R.J. Simpson, An evaluation, comparison, and accurate benchmarking of several publicly available MS/MS search algorithms: sensitivity and specificity analysis, Proteomics 5 (2005), 3475-3490.
25. W.E. Klunk, B.J. Bacskai, C.A. Mathis, S.T. Kajdasz, M.E. McLellan, M.P. Frosch, M.L. Debnath, D.P. Holt, Y. Wang and B.T. Hyman, Imaging Abeta plaques in living transgenic mice with multiphoton microscopy and methoxy-X04, a systemically administered Congo red derivative, J Neuropathol Exp Neurol 61 (2002), 797-805.
26. S. Koch, N. Donarski, K. Goetze, M. Kreckel, H.J. Stuerenburg, C. Buhmann and U. Beisiegel, Characterization of four lipoprotein classes in human cerebrospinal fluid, J Lipid Res 42 (2001), 1143-1151.
27. A.J. Link, J. Eng, D.M. Schieltz, E. Carmack, G.J. Mize, D.R. Morris, B.M. Garvik and J.R. Yates, 3rd, Direct analysis of protein complexes using mass spectrometry, Nat Biotechnol 17 (1999), 676-682.
28. I. Litvan, A. MacIntyre, C.G. Goetz, G.K. Wenning, K. Jellinger, M. Verny, J.J. Bartko, J. Jankovic, A. McKee, J.P. Brandel, K.R. Chaudhuri, E.C. Lai, L. D'Olhaberriague, R.K. Pearce and Y. Agid, Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study, Arch Neurol 55 (1998), 969-978.
29. D.A. Loeffler, A.J. DeMaggio, P.L. Juneau, C.M. Brickman, G.A. Mashour, J.H. Finkelman, N. Pomara and P.A. LeWitt, Ceruloplasmin is increased in cerebrospinal fluid in Alzheimer's disease but not Parkinson's disease, Alzheimer Dis Assoc Disord 8 (1994), 190-197.
30. S. Love, Post mortem sampling of the brain and other tissues in neurodegenerative disease, Histopathology 44 (2004), 309-317.
31. S.S. Matsuyama, A.T. Cripe and J. Joseph, Haptoglobin phenotypes in dementia of the Alzheimer type, Hum Hered 36 (1986), 93-96.
32. S. Mattis and J. Coblentz, Mental status examination for organic mental syndrome in the elderly patient, New York: Grune and Stratton, 1976.
33. M.W. McIntosh and M.S. Pepe, Combining Several Screening Tests: Optimality of the Risk Score, Biometrics 58 (2002), 657-664.
34. M.W. McIntosh, C. Drescher, B. Karlan, N. Scholler, N. Urban, K.E. Hellstrom and I. Hellstrom, Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma, Gynecol Oncol 95 (2004), 9-15.
35. I.G. McKeith, D.J. Burn, C.G. Ballard, D. Collerton, E. Jaros, C.M. Morris, A. McLaren, E.K. Perry, R. Perry, M.A. Piggott and J.T. O'Brien, Dementia with Lewy bodies. Semin Clin Neuropsychiatry 8 (2003), 46-57.
36. B.N. McLean, R.W. Luxton and E.J. Thompson, A study of immunoglobulin G in the cerebrospinal fluid of 1007 patients with suspected neurological disease using isoelectric focusing and the Log IgG-Index. A comparison and diagnostic applications, Brain 113 (1990), 1269-1289.
37. J.C. Morris, Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type, Int Psychogeriatr9 (1997), 173-176; discussion 177-178.
38. A. Olsson, H. Vanderstichele, N. Andreasen, G. De Meyer, A. Wallin, B. Holmberg, L. Rosengren, E. Vanmechelen and K. Blennow, Simultaneous Measurement of {beta}-Amyloid(1-42), Total Tau, and Phosphorylated Tau (Thr181) in Cerebrospinal Fluid by the xMAP Technology, Clin Chem 51 (2005), 336-345.
39. L. Pantoni and D. Inzitari, Abnormal penetration of haptoglobin through the blood-brain-barrier (BBB) into the cerebro-spinal fluid (CSF) in Alzheimer's disease patients, Acta Neurol Scand 91 (1995), 225.
40. M. Puchades, S.F. Hansson, C.L. Nilsson, N. Andreasen, K. Blennow and P. Davidsson, Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease, Brain Res Mol Brain Res 118 (2003), 140-146.
41. A.H. Rajput, B. Rozdilsky and A. Rajput, Accuracy of clinical diagnosis in parkinsonism - a prospective study, Can J Neurol Sci 18 (1991), 275-278.
42. R. Reitan, Validity of the Trail-Making Test as an indication of organic brain damage, Percept Mot Skills 8 (1958), 271-276.
43. P.L. Ross, Y.N. Huang, J.N. Marchese, B. Williamson, K. Parker, S. Hattan, N. Khainovski, S. Pillai, S. Dey, S. Daniels, S. Purkayastha, P. Juhasz, S. Martin, M. Bartlet-Jones, F. He, A. Jacobson and D.J. Pappin, Multiplexed Protein Quantitation in Saccharomyces cerevisiae Using Amine-reactive Isobaric Tagging Reagents, Mol Cell Proteomics 3 (2004), 1154-1169.
44. F.S. Shie, R.M. Breyer and T.J. Montine, Microglia lacking E Prostanoid Receptor subtype 2 have enhanced Abeta phagocytosis yet lack Abeta-activated neurotoxicity, Am J Pathol 166 (2005), 1163-1172.
45. R. Siman, T.K. McIntosh, K.M. Soltesz, Z. Chen, R.W. Neumar and V.L. Roberts, Proteins released from degenerating neurons are surrogate markers for acute brain damage, Neurobiol Dis 16 (2004), 311-320.
46. G.W. Small, E.D. Agdeppa, V. Kepe, N. Satyamurthy, S.C. Huang and J.R. Barrio, In vivo brain imaging of tangle burden in humans, J Mol Neurosci 19 (2002), 323-327.
47. R. Strohmeyer, Y. Shen and J. Rogers, Detection of complement alternative pathway mRNA and proteins in the Alzheimer's disease brain, Brain Res Mol Brain Res 81 (2000), 7-18.
48. M.K. Sutherland, M.J. Somerville, L.K. Yoong, C. Bergeron, M.R. Haussler and D.R. McLachlan, Reduction of vitamin D hormone receptor mRNA levels in Alzheimer as compared to Huntington hippocampus: correlation with calbindin-28k mRNA levels, Brain Res Mol Brain Res 13 (1992), 239-250.
49. H. Tomimoto, I. Akiguchi, T. Suenaga, M. Nishimura, H. Wakita, S. Nakamura and J. Kimura, Alterations of the blood-brain barrier and glial cells in white-matter lesions in cerebrovascular and Alzheimer's disease patients, Stroke 27 (1996), 2069-2074.
50. G. Torsdottir, J. Kristinsson, S. Sveinbjornsdottir, J. Snaedal and T. Johannesson, Copper, ceruloplasmin, superoxide dismutase and iron parameters in Parkinson's disease, Pharmacol Toxicol 85 (1999), 239-243.
51. D.B. Weatherly, J.A. Astwood, 3rd, T.A. Minning, C. Cavola, R.L. Tarleton and R. Orlando, A Heuristic method for assigning a false-discovery rate for protein identifications from Mascot database search results, Mol Cell Proteomics 4 (2005), 762-772.
52. J. Xu, J. Chen, E. Peskind, J. Jin, J. Eng, C. Pan, T. Montine, D. Goodlett and J. Zhang, Characterization of proteome of human cerebrospinal fluid, Int Rev of Neurobiol 73 (2006), 29-98.
53. X. Yuan, T. Russell, G. Wood and D.M. Desiderio, Analysis of the human lumbar cerebrospinal fluid proteome, Electrophoresis 23 (2002), 1185-1196.
54. J. Zhang, D.R. Goodlett, E.R. Peskind, J.F. Quinn, Y. Zhou, Q. Wang, C. Pan, E. Yi, J. Eng, R.H. Aebersold and T.J. Montine, Quantitative proteomic analysis of age-related changes in human cerebrospinal fluid, Neurobiol Aging 26 (2005), 207-227.
55. J. Zhang, D.R. Goodlett, J.F. Quinn, E. Peskind, J.A. Kaye, Y. Zhou, C. Pan, E. Yi, J. Eng, Q. Wang, R.H. Aebersold and T.J. Montine, Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease, J Alzheimers Dis 7 (2005), 125-133.
56. P.P. Zheng, T.M. Luider, R. Pieters, C.J. Avezaat, M.J. van den Bent, P.A. Sillevis Smitt and J.M. Kros, Identification of tumor-related proteins by proteomic analysis of cerebrospinal fluid from patients with primary brain tumors, J Neuropathol Exp Neurol 62 (2003), 855-862.
57. Y. Zhou, G. Gu, D.R. Goodlett, T. Zhang, C. Pan, T.J. Montine, K.S. Montine, R.H. Aebersold and J. Zhang, Analysis of alpha-synuclein-associated proteins by quantitative proteomics, J Biol Chem 279 (2004), 39155-39164.